Grants per year
Personal profile
Certifications and Licenses
| Medical Oncology | |
| Hematology | |
| Internal Medicine |
Training Experience
| 2004 | Residency, University of Chicago Hospitals |
| 2007 | Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, University of Pittsburgh
… → 2001
Research interests keywords
- Acute Leukemias
- Anemia
- Aplastic Anemia
- Chronic Leukemias
- Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Diseases
- Targeted Therapies
Fingerprint
Dive into the research topics where Jessica K Altman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Molecular mechanism underlying clonal expansion of hematopoietic stem cells
Liu, Y. (PD/PI), Abaza, Y. (Co-Investigator), Altman, J. K. (Co-Investigator) & Bartom, E. T. (Co-Investigator)
National Heart, Lung, and Blood Institute
4/1/24 → 3/31/28
Project: Research project
-
Prot #KO-MEN-007: Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloi
Altman, J. K. (PD/PI)
Quintiles, Inc., Kura Oncology, Inc.
3/12/24 → 3/12/27
Project: Research project
-
Prot #TAK-012-1501: A Phase 1/2a, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety and Efficacy of GDX012 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.
11/14/23 → 11/14/26
Project: Research project
-
Prot #2215-CL-0203: A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible fo
Altman, J. K. (PD/PI)
Parexel, Astellas Pharma Global Development, Inc.
3/13/23 → 3/13/26
Project: Research project
-
Acute myeloid leukemia management and research in 2025
Kantarjian, H. M., DiNardo, C. D., Kadia, T. M., Daver, N. G., Altman, J. K., Stein, E. M., Jabbour, E., Schiffer, C. A., Lang, A. & Ravandi, F., Jan 1 2025, In: Ca-A Cancer Journal for Clinicians. 75, 1, p. 46-67 22 p.Research output: Contribution to journal › Review article › peer-review
Open Access7 Scopus citations -
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia
Palmer, A., Rauscher, G., Abraham, I., Burkart, M., Dave, A., Raptis, N., Aleem, A., Gannamani, V., Erra, A., Monick, S., Galvez, C., Shah, S., Youshanlouei, H. R., Larson, M. L., Zia, M., Tsai, S. B., Altman, J. K., Stock, W., Khan, I. & Patel, A. A., Sep 10 2024, In: Blood Advances. 8, 17, p. 4647-4650 4 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
Bewersdorf, J. P., Shallis, R. M., Sharon, E., Park, S., Ramaswamy, R., Roe, C. E., Irish, J. M., Caldwell, A., Wei, W., Yacoub, A., Madanat, Y. F., Zeidner, J. F., Altman, J. K., Odenike, O., Yerrabothala, S., Kovacsovics, T., Podoltsev, N. A., Halene, S., Little, R. F. & Piekarz, R. & 3 others, , Jan 2024, In: Annals of Hematology. 103, 1, p. 105-116 12 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations -
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia
Levis, M., Perl, A., Schiller, G., Fathi, A. T., Roboz, G., Wang, E. S., Altman, J., Rajkhowa, T., Ando, M., Suzuki, T., Subach, R. A., Maier, G., Madden, T., Johansen, M., Cheung, K., Kurman, M. & Smith, C., May 28 2024, In: Blood Advances. 8, 10, p. 2527-2535 9 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Chronic Myeloid Leukemia, Version 2.2024
Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M., Begna, K. H., Berman, E., Chan, O., Clements, J., Collins, R. H., Curtin, P. T., DeAngelo, D. J., Drazer, M., Maness, L., Metheny, L., Mohan, S., Moore, J. O., Oehler, V., Pratz, K., Pusic, I. & Rose, M. G. & 13 others, , Feb 2024, In: JNCCN Journal of the National Comprehensive Cancer Network. 22, 1, p. 43-69 27 p.Research output: Contribution to journal › Article › peer-review
Open Access24 Scopus citations